KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Payables: 2010-2025

Historic Payables for Halozyme Therapeutics (HALO) over the last 15 years, with Sep 2025 value amounting to $15.4 million.

  • Halozyme Therapeutics' Payables rose 23.89% to $15.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $64.4 million, marking a year-over-year increase of 21.53%. This contributed to the annual value of $10.2 million for FY2024, which is 13.26% down from last year.
  • Halozyme Therapeutics' Payables amounted to $15.4 million in Q3 2025, which was down 17.82% from $18.7 million recorded in Q2 2025.
  • In the past 5 years, Halozyme Therapeutics' Payables ranged from a high of $20.1 million in Q1 2025 and a low of $535,000 during Q1 2021.
  • Its 3-year average for Payables is $14.1 million, with a median of $13.3 million in 2024.
  • Per our database at Business Quant, Halozyme Therapeutics' Payables plummeted by 93.57% in 2021 and then surged by 1,048.15% in 2022.
  • Over the past 5 years, Halozyme Therapeutics' Payables (Quarterly) stood at $1.5 million in 2021, then spiked by 1,048.15% to $17.7 million in 2022, then plummeted by 33.22% to $11.8 million in 2023, then dropped by 13.26% to $10.2 million in 2024, then grew by 23.89% to $15.4 million in 2025.
  • Its Payables was $15.4 million in Q3 2025, compared to $18.7 million in Q2 2025 and $20.1 million in Q1 2025.